Amgen bets on stem cell company Fortuna Fix in $25M round
Amgen’s venture arm just made a bet on regenerative medicine for the first time. The pharma giant pitched in to a new $25 million financing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
